Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2013, Article ID 427693, 14 pages
http://dx.doi.org/10.1155/2013/427693
Research Article

RU28318, an Aldosterone Antagonist, in Combination with an ACE Inhibitor and Angiotensin Receptor Blocker Attenuates Cardiac Dysfunction in Diabetes

1Department of Pharmacology & Toxicology, Faculty of Medicine, Kuwait University, P.O. Box 24923, 13110 Safat, Kuwait
2Department of Physiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, 13110 Safat, Kuwait
3Department of Medicine, Faculty of Medicine, Kuwait University, P.O. Box 24923, 13110 Safat, Kuwait

Received 25 April 2013; Revised 16 July 2013; Accepted 17 July 2013

Academic Editor: Daisuke Koya

Copyright © 2013 Ibrahim F. Benter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Nguyen Dinh Cat and F. Jaisser, “Extrarenal effects of aldosterone,” Current Opinion in Nephrology and Hypertension, vol. 21, no. 2, pp. 147–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. C. E. Gomez-Sanchez, M. Warden, M. T. Gomez-Sanchez, X. Hou, and E. P. Gomez-Sanchez, “Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies,” Steroids, vol. 76, no. 14, pp. 1541–1545, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J.-S. Silvestre, V. Robert, C. Heymes et al., “Myocardial production of aldosterone and corticosterone in the rat: physiological regulation,” Journal of Biological Chemistry, vol. 273, no. 9, pp. 4883–4891, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Catena, G. Colussi, L. Marzano, and L. A. Sechi, “Aldosterone and the heart: from basic research to clinical evidence,” Hormone and Metabolic Research, vol. 44, no. 3, pp. 181–187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Messaoudi, F. Azibani, C. Delcayre, and F. Jaisser, “Aldosterone, mineralocorticoid receptor, and heart failure,” Molecular and Cellular Endocrinology, vol. 350, no. 2, pp. 266–272, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. C. T. Stier Jr., P. N. Chander, and R. Rocha, “Aldosterone as a mediator in cardiovascular injury,” Cardiology in Review, vol. 10, no. 2, pp. 97–107, 2002. View at Google Scholar · View at Scopus
  7. M. J. Young and A. J. Rickard, “Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis,” Molecular and Cellular Endocrinology, vol. 350, no. 2, pp. 248–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Galuppo and J. Bauersachs, “Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances,” European Journal of Clinical Investigation, vol. 42, no. 10, pp. 1112–1120, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Swedberg, F. Zannad, J. J. V. McMurray et al., “Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure) study,” Journal of the American College of Cardiology, vol. 59, no. 18, pp. 1598–1603, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Konstantinidis, R. S. Whelan, and R. N. Kitsis, “Mechanisms of cell death in heart disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 7, pp. 1552–1562, 2012. View at Google Scholar
  11. T. Miki, S. Yuda, H. Kouzu, and T. Miura, “Diabetic cardiomyopathy: pathophysiology and clinical features,” Heart Failure Reviews, vol. 18, no. 2, pp. 149–166, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. H. J. Whittington, G. G. Babu, M. M. Mocanu, D. M. Yellon, and D. J. Hausenloy, “The diabetic heart: too sweet for its own good?” Cardiology Research and Practice, vol. 1, no. 1, Article ID 845698, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Kumar, Q. C. Yong, C. M. Thomas, and K. M. Baker, “Intracardiac intracellular angiotensin system in diabetes,” American Journal of Physiology, vol. 302, no. 5, pp. R510–R517, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Volpe, A. H. J. Danser, J. Menard et al., “Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?” Journal of Hypertension, vol. 30, no. 4, pp. 647–654, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Werner, J. Pöss, and M. Böhm, “Optimal antagonism of the renin-angiotensin-aldosterone system: do we need dual or triple therapy?” Drugs, vol. 70, no. 10, pp. 1215–1230, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. M. A. Van De Wal, H. W. M. Plokker, D. J. A. Lok et al., “Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition,” International Journal of Cardiology, vol. 106, no. 3, pp. 367–372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Andrew, “Renin-angiotensin-aldosterone activation in heart failure, aldosterone escape,” Chest, vol. 122, no. 2, article 755, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Rossignol, J. Ménard, R. Fay, F. Gustafsson, B. Pitt, and F. Zannad, “Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects: insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy,” Journal of the American College of Cardiology, vol. 58, no. 19, pp. 1958–1966, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Alfie, L. S. Aparicio, and G. D. Waisman, “Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition,” Reviews on Recent Clinical Trials, vol. 6, no. 2, pp. 134–146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. T. K. W. Ma, K. K. H. Kam, B. P. Yan, and Y.-Y. Lam, “Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status,” British Journal of Pharmacology, vol. 160, no. 6, pp. 1273–1292, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. I. F. Benter, M. H. M. Yousif, F. M. Al-Saleh, R. Raghupathy, M. C. Chappell, and D. I. Diz, “Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-l-arginine methyl ester,” Journal of Cardiovascular Pharmacology, vol. 57, no. 5, pp. 559–567, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. I. F. Benter, M. H. M. Yousif, J. T. Anim, C. Cojocel, and D. I. Diz, “Angiotensin-(1–7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME,” American Journal of Physiology, vol. 290, no. 2, pp. H684–H691, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi, and D. I. Diz, “Angiotensin-(1–7) prevents diabetes-induced cardiovascular dysfunction,” American Journal of Physiology, vol. 292, no. 1, pp. H666–H672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Unger, “The role of the renin-angiotensin system in the development of cardiovascular disease,” American Journal of Cardiology, vol. 89, no. 2, pp. 3A–10A, 2002. View at Google Scholar · View at Scopus
  25. T. G. von Lueder and H. Krum, “RAAS inhibitors and cardiovascular protection in large scale trials,” Cardiovascular Drugs and Therapy/Sponsored by the International Society of Cardiovascular PharmacoTherapy, vol. 27, no. 2, pp. 171–179, 2013. View at Google Scholar
  26. J. Wong, “Is there benefit in dual renin- angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed,” Diabetes & Vascular Disease Research, vol. 10, no. 3, pp. 193–201, 2013. View at Google Scholar
  27. H. M. McAlpine and S. M. Cobbe, “Neuroendocrine changes in acute myocardial infarction,” The American Journal of Medicine, vol. 84, no. 3, pp. 61–66, 1988. View at Google Scholar · View at Scopus
  28. R. M. A. Van De Wal, D. J. Van Veldhuisen, W. H. Van Gilst, and A. A. Voors, “Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?” European Heart Journal, vol. 26, no. 22, pp. 2361–2367, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. J. K. Boyer, S. Thanigaraj, K. B. Schechtman, and J. E. Pérez, “Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus,” American Journal of Cardiology, vol. 93, no. 7, pp. 870–875, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. T. D. Karamitsos, H. I. Karvounis, T. Didangelos, G. E. Parcharidis, and D. T. Karamitsos, “Impact of autonomic neuropathy on left ventricular function in normotensive type 1 diabetic patients: a tissue Doppler echocardiographic study,” Diabetes Care, vol. 31, no. 2, pp. 325–327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Ouvrard-Pascaud, Y. Sainte-Marie, J.-P. Bénitah et al., “Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias,” Circulation, vol. 111, no. 23, pp. 3025–3033, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Perrier, S. Richard, Y. Sainte-Marie et al., “A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice,” Journal of Physiology, vol. 569, no. 1, pp. 153–162, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Lalevée, M. C. Rebsamen, S. Barrère-Lemaire et al., “Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes,” Cardiovascular Research, vol. 67, no. 2, pp. 216–224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. A. M. Gómez, A. Rueda, Y. Sainte-Marie et al., “Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of fk506-binding proteins,” Circulation, vol. 119, no. 16, pp. 2179–2187, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Dartsch, R. Fischer, A. Gapelyuk et al., “Aldosterone induces electrical remodeling independent of hypertension,” International Journal of Cardiology, vol. 164, no. 2, pp. 170–178, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. W. C. De Mello, “Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 7, no. 1, pp. 40–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Qu, F. M. Volpicelli, L. I. Garcia et al., “Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart,” Circulation Research, vol. 104, no. 3, pp. 365–371, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. V. C. De Giusti, M. B. Nolly, A. M. Yeves et al., “Aldosterone stimulates the cardiac Na+/H+ exchanger via transactivation of the epidermal growth factor receptor,” Hypertension, vol. 58, no. 5, pp. 912–919, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Akhtar, M. H. Yousif, B. Chandrasekhar, and I. F. Benter, “Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury,” PLoS ONE, vol. 7, no. 6, Article ID e39066, 2012. View at Google Scholar
  40. S. Akhtar, M. H. M. Yousif, G. S. Dhaunsi, B. Chandrasekhar, O. Al-Farsi, and I. F. Benter, “Angiotensin-(1–7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway,” British Journal of Pharmacology, vol. 165, no. 5, pp. 1390–1400, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. M.-L. Ambroisine, J. Favre, P. Oliviero et al., “Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells,” Circulation, vol. 116, no. 21, pp. 2435–2443, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. I. F. Benter, M. Benboubetra, A. J. Hollins, M. H. M. Yousif, H. Canatan, and S. Akhtar, “Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature,” Vascular Pharmacology, vol. 51, no. 4, pp. 236–245, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. I. F. Benter, M. H. M. Yousif, S. M. Griffiths, M. Benboubetra, and S. Akhtar, “Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed,” British Journal of Pharmacology, vol. 145, no. 6, pp. 829–836, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. I. F. Benter, M. H. M. Yousif, A. J. Hollins, S. M. Griffiths, and S. Akhtar, “Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase,” Journal of Vascular Research, vol. 42, no. 4, pp. 284–291, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. J. A. Ezekowitz and F. A. McAlister, “Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials,” European Heart Journal, vol. 30, no. 4, pp. 469–477, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Düsing and F. Sellers, “ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial,” Current Medical Research and Opinion, vol. 25, no. 9, pp. 2287–2301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. J. R. Sowers, A. Whaley-Connell, and M. Epstein, “Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension,” Annals of Internal Medicine, vol. 150, no. 11, pp. 776–783, 2009. View at Google Scholar · View at Scopus
  48. P. Stiefel, A. J. Vallejo-Vaz, S. Garcia Morillo, and J. Villar, “Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome,” International Journal of Hypertension, vol. 2011, Article ID 685238, 8 pages, 2011. View at Publisher · View at Google Scholar